Norman Molyneux
[email protected]
0161 850 0156
Norman Molyneux is the founder and CEO of Acceleris
and has been putting together technology deals since
2000.
DEDICATION AND KNOWLEDGE
INVESTING IN SCIENCE - A GUIDED TOUR
AROUND ALDERLEY PARK, THE CENTRE FOR
SCIENCE IN THE NORTH
I
f you look around the world at successful scientific clusters
you see a pleasant working environment amidst world class
laboratory facilities, access to a major international hub
airport and that blend of smart financial capital working in
and around the businesses there. Alderley Park is an exciting
development because it has all those elements.
“The challenge is to build that critical mass around the
businesses that are already there, like Redx, and make it a
thriving cluster at the very centre of the North of England’s
scientific strategy.”
Norman Molyneux is speaking during a tour of Alderley
Park, a thriving hub of science and innovation in the midst
of Cheshire’s most prosperous postcode.
Since founding Acceleris in 2000 he has known where to
find good businesses and link them up with the right kind of
investment. Places like Alderley Park.
It seemed like a bitter blow to the North’s science strategy
when pharma giant AstraZeneca scaled back it’s presence at
Alderley Park in Cheshire.
But the move proved to be the catalyst for Manchester
Science Partnerships (MSP) to step in and they have revealed
plans for the first phase of development at their flagship
400-acre life science campus.
In a session, titled ‘Translating Science into Place’, at MIPIM,
a French real-estate exhibition, MSP were presented as a
key part of Manchester’s plans for innovation and growth
for the UK and a key part of Manchester’s future host city
status as ‘European City of Science 2016’.
The plans signal the first major step for MSP’s vision to
transform Alderley Park, AstraZeneca’s former research
hub, into an open community for life science businesses,
with over 7,000 high-value jobs planned on-site in the next
decade.
13